-
Innovation Ranking
NewInnovation Ranking – Formosa Taffeta Co Ltd
Formosa Taffeta Co Ltd (Formosa Taffeta) is a textile company that manufactures fibers. Its products include special finishes fabric, home and comfort fabric, safety, and life fabric, rainy and sunshine fabric; sports and casual fabric; ladies and gentleman's fashion fabric, tire cord fabric, and pe plastic bags. It provides fabric design, weaving, dyeing, printing, and finishing. Formosa Taffeta’s PE Plastic Bags offer produce roll bags, t-shirt bags, and garbage bags. It also provides outdoor fabrics, carbon fiber, and others. The...
-
Innovation Ranking
NewInnovation Ranking – Formosa Plastics Corp
Formosa Plastics Corp (FPC), a subsidiary of Formosa Plastics Group, is a chemical manufacturing company. It manufactures and markets intermediate raw materials for plastics. The company’s product portfolio includes polyvinyl chloride (PVC) resins, vinyl chloride monomers (VCM), flake caustic soda, caustic soda, hydrochloric acid, high-density polyethylene (HDPE), ethylene-vinyl acetate (EVA)/low-density polyethylene (LDPE), and linear low-density polyethylene (LLDPE). FPC also provides calcium carbonate products; electronic systems such as automatic store/retrieve, automation, advanced process control, and power management systems, programming software and...
-
Sector Analysis
NewPetrochemicals Capacity and Capital Expenditure Outlook by Region, Countries, Companies, Commodity, Projects and Forecast to 2030
Petrochemicals Capacity & Capital Expenditure (Capex) Overview The petrochemicals capacity was 2600.06 million tonnes per annum (mtpa) in 2023. Asia, the Middle East, and the Former Soviet Union are the top regions contributing to capacity additions in the upcoming years. In the Middle East, most capacity additions are in Iran while in FSU, the majority of capacity additions are in Russia. Petrochemicals Capacity and Capex Outlook, 2023-2030 (mtpa) Buy the Full Report for More Insights on Petrochemicals Capacity and Capex...
-
Sector Analysis
NewAcrylonitrile Industry Capacity and Capital Expenditure Forecasts with Details of All Active and Planned Plants to 2028
Acrylonitrile Industry Capacity & Capital Expenditure (Capex) Overview The acrylonitrile industry capacity was 9.55 million tonnes per annum (mtpa) in 2023. China, the US, South Korea, Japan, and Taiwan were the key countries accounting for most of the acrylonitrile capacity in 2023. The acrylonitrile industry capacity will garner an AAGR of more than 4% from 2023 to 2028. In terms of global Capex spending non acrylonitrile industry planned and announced projects, Asia will account for the largest regional share with...
-
Sector Analysis
Ethylene Glycol Industry Capacity and Capital Expenditure Forecasts with Details of All Active and Planned Plants to 2028
Ethylene Glycol Industry Capacity & CapEx Overview The Ethylene Glycol industry capacity was 60.06 million tonnes per annum (mtpa) in 2023 and it is expected to increase at an AAGR of more than 5% during 2023-2028. Around 40 planned and announced plants are slated to come online by 2028, primarily in Asia and the Middle East. This will boost the market growth during the forecast years. Ethylene Glycol Industry Capacity and CapEx Outlook, 2023-2028 (mtpa) Buy the Full Report for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Linrodostat Mesylate in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Linrodostat Mesylate in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Linrodostat Mesylate in Adenocarcinoma Of The Gastroesophageal Junction...
-
Product Insights
Conjunctivitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Conjunctivitis - Drugs In Development, 2023’, provides an overview of the Conjunctivitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Blepharitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Blepharitis - Drugs In Development, 2023’, provides an overview of the Blepharitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Blepharitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MPT-0E028 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MPT-0E028 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MPT-0E028 in Solid Tumor Drug Details: MPT-0E028 is under development for...